## Enabling technologies for synthesis and functionalization of sp3-rich molecules in Medicinal Chemistry

## **Quentin Lefebvre**

SpiroChem AG, Rosental area, WRO-1047-3, Mattenstrasse 22, 4058 Basel, Switzerland

R&D Leader SpiroChem AG www.spirochem.com

Compounds and intermediates in medicinal chemistry often present a bias toward the presence of multiple aromatic rings, as palladium-cross-coupling reactions have emerged as robust and versatile methodologies. Although synthetically tractable, such sp²-rich compounds exhibit lower metabolic stability and less desirable physical-organic properties compared to their sp³-rich counterparts. Thus, strategies to "escape from flatland" are highly desirable in medicinal chemistry programs.

In this talk, Dr. Quentin Lefebvre will demonstrate how SpiroChem leverages modern methodologies and technologies for the efficient synthesis and functionalization of sp<sup>3</sup>-rich molecules, creating a synthetic toolbox by combining strategic academic collaborations and internal R&D programs.